RCP says pharmacologists should fund clinical trials of cannabis products
Tetrahydrocannabidol has propsychotic and anxiogenic properties, therefore, "it is highly unlikely that future psychiatric indications for drugs containing THC will be found in future studies." Cannabidiol is “by far the most promising component of hemp” for the treatment of mental disorders.
Despite the fact that people with psychosis, social anxiety disorders, or post-traumatic stress disorder can potentially benefit from cannabis-based pharmacological agents, Royal College of Psychiatrists ( UK ) has officially stated that the published data used as evidence of benefits for health "need substantial improvement." In particular, it is said that without evidence from randomized controlled trials, cannabis prescribing in the UK would be an extremely challenging exercise.
In a statement, officials of Royal College of Psychiatrists (Royal College of Psychiatrists), raised the issue that there is an "urgent need" for high-quality studies of the use of drugs based on cannabis ( of cannabis-based medicinal products, CBMP ) for the treatment of mental disorders. Representatives of RCPsych focus on the fact that pharmaceutical companies are "not interested" in investing in randomized controlled trials (RCTs). But without the provision of data on such tests, prescriptions for the use of hemp-based medicines in the United Kingdom cannot be officially used by medical personnel. Representatives of the Royal College of Psychiatrists say that psychoses, social anxiety disorders, post-traumatic stress disorder, and “achieving abstinence from addictive substances” are examples of conditions under which CBPM can be beneficial, but warn that available evidence is “rare and in need in significant improvement. "
Adrian James, registrar of the Royal College of Psychiatrists, argues that, despite the “acute shortage of high-quality proven data confirming the effective use of cannabis-based medicines ,” there is little evidence to support their use in mental disorders. We welcome evidence of the potential benefits of cannabis-based drugs , but we caution that most of them come from small studies, and the low level of worldwide use means that the side effect and risk profile are insufficiently confirmed. To fix this and gather evidence that patients and doctors need this kind of material, key organizations must be proactive in order to reduce the barriers that exist for this kind of research. ”
According to representatives of the Royal College of Psychiatrists, CBPM efficacy monitoring data may show “significantly higher efficacy - sometimes an order of magnitude” compared to RCTs — which is why randomized controlled trials are “necessary and will play an important role in establishing the evidence base for pharmaceutical use cannabis preparations . " That is why representatives of the Royal College of Psychiatrists argue that the government and patient groups can and should put pressure on pharmaceutical companies to start this kind of research.
The above statement echoes the view expressed by Dame Sally Davies, the former chief medical officer of England , who told parliamentarians in early 2019 that “the time has come when the pharmaceutical industry begins to talk about what it intends to do with test funding in order to obtain licenses for the use of hemp-based medicines . ” Mr. Dame Sally Davis claims that tetrahydrocannabidol (THC) has propsychotic and anxiogenic properties, so “it is highly unlikely that future psychiatric indications for drugs containing THC will be found.” Cannabidiol is “by far the most promising component of hemp” for the treatment of mental disorders.
Commentary of the Ukrainian Technical Hemp Association
Up-to-date information on the possibilities of using therapeutic therapeutic hemp can be obtained during the round table held on December 17, 2019 “ The use of cannabinoids in the treatment of severe / chronic diseases ”, held as part of the “ Hemp University ”.